This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
High titers of anti-Hu antibodies indicate the paraneoplastic genesis of neurologic syndromes with high specifity.1,2⇓ In most cases, the primary tumor is identified as small cell lung cancer (SCLC); reports of other tumors are rare.2,3⇓ Here, we report a patient positive for anti-Hu antibodies who developed a sensory neuropathy and Holmes–Adie syndrome (HAS). The only tumor that was detected was a unilateral seminoma. After tumor removal, anti-Hu antibodies eventually vanished.
Case report.
The then 31-year-old patient was first admitted to the hospital in June 2000 with a 6-week history of hypoesthesia and paresthesia of his feet. He was a nonsmoker and had no relevant past or family history. Neurologic examination revealed missing Achilles tendon reflexes, marked decrease in proprioceptive and kinesthetic sensation in both feet, and mild sensory gait ataxia. CSF showed elevated protein levels (1,747 mg/L); all other findings, including oligoclonal bands and tests for borreliosis and syphilis, were normal, as were serum tests for autoantibodies, diabetes, folic acid, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Reversible Paraneoplastic Tonic Pupil with PCA-Tr IgG and Hodgkin Lymphoma
Pearls & Oy-sters: Anisocoria Greater in the Dark: It's Not Just All About Horner Pupil
Treatment of Guillain-Barré Syndrome with Intravenous Immunoglobulin
Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain–Barré syndrome